AYER, Mass.--(BUSINESS WIRE)--Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition, introduced KetoVie 4:1, an advanced nutritional solution for use with the ketogenic diet.
KetoVie 4:1 is a Medical Food for the dietary management of intractable epilepsy and other disorders requiring ketogenic therapy. The advanced KetoVie 4:1 is nutritionally complete and addresses the most common nutritional shortcomings associated with the ketogenic diet.
“Cambrooke is a mission-driven company focused on providing the most nutritious, best tasting and healthful Medical Foods and functional foods for those living with chronic conditions,” said CEO Howard Lossing, “We have developed great relationships with many leading medical professionals prescribing ketogenic diet therapy and knew we could advance the quality of nutritional support for their patients well beyond what was currently available.”
KetoVie 4:1 is a nutritionally complete liquid, appropriate as both an oral and tube feed and designed to help address the most common challenges associated with the ketogenic diet that could be addressed via a nutritional formulation. KetoVie 4:1 is the only ketogenic diet Medical Food to contain 100% fast absorbing whey protein, MCT and DHA oils, potassium and sodium citrates, carnitine and selenium, soluble and insoluble fibers and has only one gram net carbohydrate per serving.
“As a former practicing clinician of ketogenic diet therapy, I know the challenges families face in managing the diet’s complexity,” said Cambrooke’s Director of Clinical Nutrition, Susan Gingrich, RD, “With KetoVie, we sought to reduce this complexity to improve compliance and patient outcomes. Our commitment to ketogenic therapy has just started. Soon we will have more great news for these families.”
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.
About Galen Partners – Galen Partners is a leading health care private equity investment firm based in Stamford, Conn. The firm focuses on growth equity investments in health care technology-enabled services, medical devices, and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 70 companies since 1990. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build health care market leaders.
